131TiP ASCEND: Randomized, double-blinded phase II study of gemcitabine and nab-paclitaxel with CEND-1 or placebo in untreated metastatic pancreatic ductal adenocarcinoma - An Australasian Gastro-Intestinal Trials Group (AGITG) trial ACTRN12621001290886.

Authors :: Dean, A.
Price, T.J.
Sjoquist, K.
Aryal, N.
Mumford, J.
Day, F.
Yip, S.
Walsh, A.
Siu, D.
Jackson, C.
Padinharakam, S.
Lee, B.
Burge, M.
Lynam, J.
Tebbutt, N.
Wong, Z.W.J.
Lam, L.L.
Lee, J.
Chantrill, L.
Harris, M.
Source :: Annals of Oncology. Nov2022 Suppl 9, Vol. 33, pS1483-S1483. 1p.
Publication Year :: 2022

Subjects :: *PANCREATIC duct
*GEMCITABINE
*ADENOCARCINOMA
*PLACEBOS
*METASTASIS

Full Text Access

Tools